Stanford Taylor1, James M Brown2, Kishan Gupta1, J Peter Campbell1, Susan Ostmo1, R V Paul Chan3, Jennifer Dy4, Deniz Erdogmus4, Stratis Ioannidis4, Sang J Kim1,5, Jayashree Kalpathy-Cramer2,6, Michael F Chiang1,7. 1. Department of Ophthalmology, Casey Eye institute, Oregon Health & Science University, Portland. 2. Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Charlestown. 3. Department of Ophthalmology and Visual Sciences, Illinois Eye and Ear Infirmary, University of Illinois at Chicago, Chicago. 4. Department of Electrical and Computer Engineering, Northeastern University, Boston, Massachusetts. 5. Department of Ophthalmology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea. 6. Massachusetts General Hospital and Brigham and Women's Hospital Center for Clinical Data Science, Boston. 7. Department of Medical Informatics and Clinical Epidemiology, Oregon Health & Science University, Portland.
Abstract
IMPORTANCE: Retinopathy of prematurity (ROP) is a leading cause of childhood blindness worldwide, but clinical diagnosis is subjective and qualitative. OBJECTIVE: To describe a quantitative ROP severity score derived using a deep learning algorithm designed to evaluate plus disease and to assess its utility for objectively monitoring ROP progression. DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study included images from 5255 clinical examinations of 871 premature infants who met the ROP screening criteria of the Imaging and Informatics in ROP (i-ROP) Consortium, which comprises 9 tertiary care centers in North America, from July 1, 2011, to December 31, 2016. Data analysis was performed from July 2017 to May 2018. EXPOSURE: A deep learning algorithm was used to assign a continuous ROP vascular severity score from 1 (most normal) to 9 (most severe) at each examination based on a single posterior photograph compared with a reference standard diagnosis (RSD) simplified into 4 categories: no ROP, mild ROP, type 2 ROP or pre-plus disease, or type 1 ROP. Disease course was assessed longitudinally across multiple examinations for all patients. MAIN OUTCOMES AND MEASURES: Mean ROP vascular severity score progression over time compared with the RSD. RESULTS: A total of 5255 clinical examinations from 871 infants (mean [SD] gestational age, 27.0 [2.0] weeks; 493 [56.6%] male; mean [SD] birth weight, 949 [271] g) were analyzed. The median severity scores for each category were as follows: 1.1 (interquartile range [IQR], 1.0-1.5) (no ROP), 1.5 (IQR, 1.1-3.4) (mild ROP), 4.6 (IQR, 2.4-5.3) (type 2 and pre-plus), and 7.5 (IQR, 5.0-8.7) (treatment-requiring ROP) (P < .001). When the long-term differences in the median severity scores across time between the eyes progressing to treatment and those who did not eventually require treatment were compared, the median score was higher in the treatment group by 0.06 at 30 to 32 weeks, 0.75 at 32 to 34 weeks, 3.56 at 34 to 36 weeks, 3.71 at 36 to 38 weeks, and 3.24 at 38 to 40 weeks postmenstrual age (P < .001 for all comparisons). CONCLUSIONS AND RELEVANCE: The findings suggest that the proposed ROP vascular severity score is associated with category of disease at a given point in time and clinical progression of ROP in premature infants. Automated image analysis may be used to quantify clinical disease progression and identify infants at high risk for eventually developing treatment-requiring ROP. This finding has implications for quality and delivery of ROP care and for future approaches to disease classification.
IMPORTANCE: Retinopathy of prematurity (ROP) is a leading cause of childhood blindness worldwide, but clinical diagnosis is subjective and qualitative. OBJECTIVE: To describe a quantitative ROP severity score derived using a deep learning algorithm designed to evaluate plus disease and to assess its utility for objectively monitoring ROP progression. DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study included images from 5255 clinical examinations of 871 premature infants who met the ROP screening criteria of the Imaging and Informatics in ROP (i-ROP) Consortium, which comprises 9 tertiary care centers in North America, from July 1, 2011, to December 31, 2016. Data analysis was performed from July 2017 to May 2018. EXPOSURE: A deep learning algorithm was used to assign a continuous ROP vascular severity score from 1 (most normal) to 9 (most severe) at each examination based on a single posterior photograph compared with a reference standard diagnosis (RSD) simplified into 4 categories: no ROP, mild ROP, type 2 ROP or pre-plus disease, or type 1 ROP. Disease course was assessed longitudinally across multiple examinations for all patients. MAIN OUTCOMES AND MEASURES: Mean ROP vascular severity score progression over time compared with the RSD. RESULTS: A total of 5255 clinical examinations from 871 infants (mean [SD] gestational age, 27.0 [2.0] weeks; 493 [56.6%] male; mean [SD] birth weight, 949 [271] g) were analyzed. The median severity scores for each category were as follows: 1.1 (interquartile range [IQR], 1.0-1.5) (no ROP), 1.5 (IQR, 1.1-3.4) (mild ROP), 4.6 (IQR, 2.4-5.3) (type 2 and pre-plus), and 7.5 (IQR, 5.0-8.7) (treatment-requiring ROP) (P < .001). When the long-term differences in the median severity scores across time between the eyes progressing to treatment and those who did not eventually require treatment were compared, the median score was higher in the treatment group by 0.06 at 30 to 32 weeks, 0.75 at 32 to 34 weeks, 3.56 at 34 to 36 weeks, 3.71 at 36 to 38 weeks, and 3.24 at 38 to 40 weeks postmenstrual age (P < .001 for all comparisons). CONCLUSIONS AND RELEVANCE: The findings suggest that the proposed ROP vascular severity score is associated with category of disease at a given point in time and clinical progression of ROP in premature infants. Automated image analysis may be used to quantify clinical disease progression and identify infants at high risk for eventually developing treatment-requiring ROP. This finding has implications for quality and delivery of ROP care and for future approaches to disease classification.
Authors: Preeti J Thyparampil; Yangseon Park; M E Martinez-Perez; Thomas C Lee; David J Weissgold; Audina M Berrocal; R V Paul Chan; John T Flynn; Michael F Chiang Journal: Am J Ophthalmol Date: 2010-10 Impact factor: 5.258
Authors: Travis K Redd; John Peter Campbell; James M Brown; Sang Jin Kim; Susan Ostmo; Robison Vernon Paul Chan; Jennifer Dy; Deniz Erdogmus; Stratis Ioannidis; Jayashree Kalpathy-Cramer; Michael F Chiang Journal: Br J Ophthalmol Date: 2018-11-23 Impact factor: 4.638
Authors: J Peter Campbell; Jayashree Kalpathy-Cramer; Deniz Erdogmus; Peng Tian; Dharanish Kedarisetti; Chace Moleta; James D Reynolds; Kelly Hutcheson; Michael J Shapiro; Michael X Repka; Philip Ferrone; Kimberly Drenser; Jason Horowitz; Kemal Sonmez; Ryan Swan; Susan Ostmo; Karyn E Jonas; R V Paul Chan; Michael F Chiang Journal: Ophthalmology Date: 2016-08-31 Impact factor: 12.079
Authors: James D Reynolds; Velma Dobson; Graham E Quinn; Alistair R Fielder; Earl A Palmer; Richard A Saunders; Robert J Hardy; Dale L Phelps; John D Baker; Michael T Trese; David Schaffer; Betty Tung Journal: Arch Ophthalmol Date: 2002-11
Authors: Emily A McCourt; Gui-Shuang Ying; Anne M Lynch; Alan G Palestine; Brandie D Wagner; Erica Wymore; Lauren A Tomlinson; Gil Binenbaum Journal: JAMA Ophthalmol Date: 2018-04-01 Impact factor: 7.389
Authors: Jayashree Kalpathy-Cramer; J Peter Campbell; Deniz Erdogmus; Peng Tian; Dharanish Kedarisetti; Chace Moleta; James D Reynolds; Kelly Hutcheson; Michael J Shapiro; Michael X Repka; Philip Ferrone; Kimberly Drenser; Jason Horowitz; Kemal Sonmez; Ryan Swan; Susan Ostmo; Karyn E Jonas; R V Paul Chan; Michael F Chiang Journal: Ophthalmology Date: 2016-08-24 Impact factor: 12.079
Authors: Kishan Gupta; J Peter Campbell; Stanford Taylor; James M Brown; Susan Ostmo; R V Paul Chan; Jennifer Dy; Deniz Erdogmus; Stratis Ioannidis; Jayashree Kalpathy-Cramer; Sang J Kim; Michael F Chiang Journal: JAMA Ophthalmol Date: 2019-07-03 Impact factor: 7.389
Authors: Rene Y Choi; James M Brown; Jayashree Kalpathy-Cramer; R V Paul Chan; Susan Ostmo; Michael F Chiang; J Peter Campbell Journal: Ophthalmol Retina Date: 2020-05-04
Authors: Kellyn N Bellsmith; James Brown; Sang Jin Kim; Isaac H Goldstein; Aaron Coyner; Susan Ostmo; Kishan Gupta; R V Paul Chan; Jayashree Kalpathy-Cramer; Michael F Chiang; J Peter Campbell Journal: Ophthalmology Date: 2020-02-07 Impact factor: 12.079
Authors: Kishan Gupta; J Peter Campbell; Stanford Taylor; James M Brown; Susan Ostmo; R V Paul Chan; Jennifer Dy; Deniz Erdogmus; Stratis Ioannidis; Jayashree Kalpathy-Cramer; Sang J Kim; Michael F Chiang Journal: JAMA Ophthalmol Date: 2019-07-03 Impact factor: 7.389
Authors: J Peter Campbell; Praveer Singh; Travis K Redd; James M Brown; Parag K Shah; Prema Subramanian; Renu Rajan; Nita Valikodath; Emily Cole; Susan Ostmo; R V Paul Chan; Narendran Venkatapathy; Michael F Chiang; Jayashree Kalpathy-Cramer Journal: Pediatrics Date: 2021-03 Impact factor: 7.124
Authors: Nita G Valikodath; Tala Al-Khaled; Emily Cole; Daniel S W Ting; Elmer Y Tu; J Peter Campbell; Michael F Chiang; Joelle A Hallak; R V Paul Chan Journal: J AAPOS Date: 2021-06-01 Impact factor: 1.325
Authors: Hao Tan; Patricia Blasco; Tamorah Lewis; Susan Ostmo; Michael F Chiang; John Peter Campbell Journal: Surv Ophthalmol Date: 2021-03-02 Impact factor: 6.197
Authors: Nita G Valikodath; Emily Cole; Daniel S W Ting; J Peter Campbell; Louis R Pasquale; Michael F Chiang; R V Paul Chan Journal: Transl Vis Sci Technol Date: 2021-06-01 Impact factor: 3.283